Publications by authors named "Ben Zweifel"

Claim this Profile
D
Distinct binding and signaling activity of Acthar Gel compared to other melanocortin receptor agonists.
Y Joyce Huang, Karen Galen, Ben Zweifel, Leah R Brooks, A Dale Wright

J Recept Signal Transduct Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PAS kinase drives lipogenesis through SREBP-1 maturation.
Xiaoying Wu, Donna Romero, Wojciech I Swiatek, Irene Dorweiler, Chintan K Kikani, Ben S Zweifel

Cell Rep· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leukotrienes, but not angiotensin II, are involved in the renal effects elicited by the prolonged cyclooxygenase-2 inhibition when sodium intake is low.
Francisco Salazar, F Javier Salazar, Fara Saez, Virginia Reverte, Ben Zweifel

J Cardiovasc Pharmacol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation.
Graciela B Arhancet, Daniel P Walker, Sue Metz, Yvette M Fobian, Steven E Heasley, Ben Zweifel

Bioorg Med Chem Lett· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain.
Jaime L Masferrer, Ben S Zweifel, Medora Hardy, Gary D Anderson, Dawn Dufield

J Pharmacol Exp Ther· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation.
James Gierse, Atli Thorarensen, Konstantine Beltey, Erica Bradshaw-Pierce, Luz Cortes-Burgos, Ben Zweifel

J Pharmacol Exp Ther· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biochemical, cellular, and anti-inflammatory properties of a potent, selective, orally bioavailable benzamide inhibitor of Rho kinase activity.
Lakshman E Rajagopalan, Michael S Davies, Larry E Kahn, Christine M Kornmeier, Hideaki Shimada, Ben S Zweifel

J Pharmacol Exp Ther· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor.
Gabriel Mbalaviele, Adele M Pauley, Alexander F Shaffer, Ben S Zweifel, Sumathy Mathialagan

Biochem Pharmacol· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain.
Luz A Cortes-Burgos, Ben S Zweifel, Steven L Settle, Robert A Pufahl, Gary D Anderson

Eur J Pharmacol· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.
Ben S Zweifel, Medora M Hardy, Gary D Anderson, Dawn R Dufield, Robert A Pufahl

Eur J Pharmacol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzymologic and pharmacologic profile of loxoprofen sodium and its metabolites.
Masahiro Noguchi, Aishi Kimoto, James Kevin Gierse, Mark Crossfield Walker, Ben Scott Zweifel

Biol Pharm Bull· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COX-2 inhibitors and genetic background reduce mammary tumorigenesis in cyclooxygenase-2 transgenic mice.
Kirsi Narko, Ben Zweifel, Ovidiu Trifan, Ari Ristimäki, Timothy F Lane

Prostaglandins Other Lipid Mediat· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.
James K Gierse, Yan Zhang, William F Hood, Mark C Walker, Jennifer S Trigg, Ben S Zweifel

J Pharmacol Exp Ther· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting.
Thomas W Davis, Ben S Zweifel, Janet M O'Neal, Deborah M Heuvelman, Ann L Abegg

J Pharmacol Exp Ther· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature.
Thomas W Davis, Janet M O'Neal, Mark D Pagel, Ben S Zweifel, Pramod P Mehta

Cancer Res· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice.
Susan Lanza-Jacoby, Sheldon Miller, John Flynn, Kathleen Gallatig, Constantine Daskalakis, Ben S Zweifel

Cancer Epidemiol Biomarkers Prev· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment.
Traci A Wilgus, Alane T Koki, Ben S Zweifel, Donna F Kusewitt, Patricia A Rubal

Mol Carcinog· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapeutic efficacy of topical celecoxib in a murine model of ultraviolet light B-induced skin cancer.
Traci A Wilgus, Alane T Koki, Ben S Zweifel, Patricia A Rubal, Tatiana M Oberyszyn

Mol Carcinog· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
Ben S Zweifel, Thomas W Davis, Richard L Ornberg, Jaime L Masferrer

Cancer Res· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.
Ovidiu C Trifan, William F Durham, Valerie S Salazar, Jennifer Horton, Benjamin D Levine, Ben S Zweifel

Cancer Res· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.
Kathleen M Leahy, Richard L Ornberg, Yu Wang, Ben S Zweifel, Alane T Koki

Cancer Res· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective inhibition of Delta-6 desaturase impedes intestinal tumorigenesis.
Melissa B Hansen-Petrik, Michael F McEntee, Benjamin T Johnson, Mark G Obukowicz, Jaime Masferrer, Ben Zweifel

Cancer Lett· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of Cyclooxygenase-2 in Inflammation.
Jaime L. Masferrer, Ben S. Zweifel, Susan M. Colburn, Richard L. Ornberg, Daniela Salvemini

Am J Ther· September 1995

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis